We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

LGC Clinical Diagnostics

LGC Clinical Diagnostics is a leading provider of Quality Measurement Tools, biological materials, and reagents for t... read more Featured Products: More products

Download Mobile App

LGC Clinical Diagnostics Acquires Urinalysis Quality Controls Provider Kova International

By LabMedica International staff writers
Posted on 25 Jul 2023
Print article
Image: KOVA-Trol and KOVA Liqua-Tro urinalysis controls are intended for use in the clinical laboratory (Photo courtesy of Kova International)
Image: KOVA-Trol and KOVA Liqua-Tro urinalysis controls are intended for use in the clinical laboratory (Photo courtesy of Kova International)

LGC Clinical Diagnostics (Middlesex, UK), a business unit of LGC and a leading provider of biological materials and viral antigens, has acquired Kova International, Inc. (Garden Grove, CA, USA), a developer and manufacturer of in vitro urinalysis and toxicology quality control products for clinical laboratories. Kova has two manufacturing facilities, one focusing on urinalysis quality controls and the other on toxicology quality controls. Both the manufacturing facilities are certified to ISO 13485:2016 quality management system standards and guidelines, as well as cGMP qualified to manufacture quality control products, and are registered FDA manufacturing sites for the clinical diagnostic laboratory industry.

Kova’s quality control products are employed in hospitals, employee wellness programs, forensic testing and medical device manufacturers production and Quality Assurance (QA) programs. The acquisition expands LGC Clinical Diagnostics’ clinical quality control portfolio, complementing its wide range of offerings across biochemistry, serology, molecular, and clinical genomics quality controls and reference materials. LGC Clinical Diagnostics has over 35 years of industry experience and caters to more than 20,000 customers in over 100 counties. The company is keen on combining Kova’s expertise with its own in order to offer its customers unmatched solutions with expanded capabilities.

“We are excited to bring Kova’s established clinical urinalysis and toxicology quality controls into LGC Clinical Diagnostics,” said Bharathi Anekella, Executive Vice President & General Manager of LGC Clinical Diagnostics. “Kova and LGC Clinical Diagnostics are an excellent fit. Our focus on delivering confidence to clinical laboratories in test precision, accuracy, and conformance to international standards, perfectly aligns us with a common objective of Science for a Safer World.”

Related Links:
Kova International, Inc.

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Magnetic Bead Separation Modules

Print article


Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more


view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.